Your cart
Your cart is empty
Continue shopping
Bundle & Save
Pharmacor
Posaconazole
Sale price
$77.99
-31%
Regular price
$112.65
Regular price
$77.99
Unit price
per
Low stock
In stock, ready to ship
Product Sold Out
Loading...
More Information (API / 100mg x 24 Tabs)
Active Ingredients
posaconazole 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
Posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Tablet Description
Pharmacor Posaconazole modified release tablets is yellow, coated, capsule-shapred tablet containing 100 mg of posaconazole.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (Sigma / 100mg x 24 Tabs)
Active Ingredients
posaconazole 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
Posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Tablet Description
Pharmacor Posaconazole modified release tablets is yellow, coated, capsule-shapred tablet containing 100 mg of posaconazole.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (Symbion / 100mg x 24 Tabs)
Active Ingredients
posaconazole 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
Posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Tablet Description
Pharmacor Posaconazole modified release tablets is yellow, coated, capsule-shapred tablet containing 100 mg of posaconazole.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
More Information (CH2 / 100mg x 24 Tabs)
Active Ingredients
posaconazole 100mg
Free-From
Gluten free
Gelatin free
Lactose free
Indicators
Posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.
Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,Posaconazole is also indicated for the:
Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.
Tablet Description
Pharmacor Posaconazole modified release tablets is yellow, coated, capsule-shapred tablet containing 100 mg of posaconazole.
Storage Conditions
Store below 25 degrees Celsius
Additional Information
Warnings
Connecting Care, Simplifying Supply.
At Pharmacor, we bridge the gap between healthcare providers and seamless supply solutions, ensuring care is always within reach.
